Sei Investments Co. Sells 307,031 Shares of Grifols, S.A. (NASDAQ:GRFS)

Sei Investments Co. trimmed its holdings in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 14.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,862,930 shares of the biotechnology company's stock after selling 307,031 shares during the period. Sei Investments Co. owned 0.27% of Grifols worth $13,860,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GRFS. R Squared Ltd bought a new stake in shares of Grifols during the fourth quarter worth $28,000. GAMMA Investing LLC lifted its holdings in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 1,527 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after buying an additional 4,970 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new position in Grifols in the 4th quarter worth $77,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Grifols during the fourth quarter worth about $91,000.

Grifols Stock Performance

GRFS stock traded up $0.53 during trading hours on Wednesday, reaching $7.49. The stock had a trading volume of 1,912,197 shares, compared to its average volume of 1,237,080. The stock has a market capitalization of $5.15 billion, a PE ratio of 6.40 and a beta of 0.35. The stock has a 50-day simple moving average of $7.55 and a 200 day simple moving average of $8.01. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley initiated coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.